In addition, several pharmaceutical companies are currently testing different small-molecule inhibitors of IRAK4 as potential drugs against rheumatoid arthritis, inflammatory bowel disease, and hematologic malignancies [27]. Here, IRAK4 is linked to rheumatoid arthritis.